Recombinant respiratory syncytial virus pre-fusion F protein antigen
RSV Infection
Medical University of ViennavaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the RSV Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nirsevimab Menzies School of Health Research | Phase 4 | BB |
Same molecule, other indications
Recombinant respiratory syncytial virus pre-fusion F protein antigen is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →